Study S001146

Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02449603
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 150
Start: 2015-11
Primary completion: 2018-04
Lead sponsor: Xijing Hospital
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Exenatide; DRUG:Biphasic insulin Aspart 30
Results posted: FALSE

Registered primary outcomes

Change of mean amplitude of glycemic excursions [from baseline to Week 16]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023224	Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial. Wang L, Diabetes therapy : research, treatment and education of diabetes and related disorders	2020	Randomized trial	PMID 32856226 DOI	cites ClinicalTrials.gov:NCT02449603; registry reference DERIVED:32856226
R0025991	Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial. Xu S, Trials	2016	Protocol	PMID 27009108 DOI	cites ClinicalTrials.gov:NCT02449603; registry reference DERIVED:27009108